Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
PTX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume766.17K
Average Volume (3M)690.15K
Market Cap
AU$59.94M
Enterprise ValueAU$51.72M
Total Cash (Recent Filing)AU$9.77M
Total Debt (Recent Filing)AU$495.89K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong ~44% revenue growth in 2025 shows meaningful top-line expansion despite the early biotech stage. If sustained, growing revenue improves the company's ability to fund operations, negotiate better partnership terms, and supports continued pipeline investment while reducing reliance on dilutive capital.
Low LeverageMinimal debt reduces refinancing and interest-rate risk, preserving financial flexibility for a cash-burning biotech. Low leverage lets management prioritize R&D and strategic partnerships without near-term debt service obligations, supporting longer-term program funding options and resilience to rate moves.
High Gross ProfitConsistently high gross profit implies favorable economics on revenue-generating activities. As the company scales or commercializes candidates, strong gross margins provide room to absorb R&D and SG&A, enabling operating leverage and a clearer path toward sustainable profitability once revenues scale further.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow, with FCF deteriorating in 2025, creates ongoing dependence on external funding. This elevates dilution and execution risk, constrains strategic choices, and threatens runway unless financing, partnerships, or a material shift in cash generation occurs.
Structural LossesPersistent operating losses and negative returns on equity erode shareholder capital over time and limit internal capacity to self-fund development. Continued structural unprofitability increases reliance on capital markets or partner deals and heightens the risk of dilution and constrained strategic flexibility.
Very Small TeamA headcount of three indicates limited internal resources to manage multiple clinical, regulatory, and commercialization activities. Heavy reliance on external contractors or partners raises execution risk, can slow program timelines, and may increase costs or coordination complexity versus better-staffed peers.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$59.94M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 170 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Feb 20, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
-49.72%
Trailing 12-Months
Asset Growth
-28.59%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Starpharma Holdings Limited
―
Avecho Biotechnology Limited
―
Chimeric Therapeutics Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---